Literature DB >> 21370005

Standardization in immunohistology.

Anthony S-Y Leong1, Trishe Y-M Leong.   

Abstract

The rapid acceptance of immunohistology as an invaluable adjunct to morphologic diagnosis has been possible because of the development of new and more sensitive antibodies and detection systems that allow its application to formalin-fixed, paraffin-embedded tissue (FFPT). More importantly, antigen-retrieval techniques have resulted in some degree of consistency allowing immunohistology to be used reliably as a diagnostic tool. The advent of prognostic and predictive biomarkers, and the desire for individualized therapy has resulted in mounting pressure to employ the immunohistological assay in a quantitative manner. While it was not a major issue when the technique was employed in a qualitative manner, the numerous variables in the preanalytical and analytical phases of the test procedure that influence the immunoexpression of proteins in FFPT become critical to standardization. Tissue fixation is pivotal to antigen preservation but exposure to fixative prior to accessioning by the laboratory is not controlled. Antigen retrieval, crucial in the analytical phase, continues to be employed in an empirical manner with the actual mechanism of action remaining elusive. There is great variation in reagents, methodology, and duration of tissue processing and immunostaining procedure, and the detection systems employed are not standardized between laboratories. While many of these variables are offset by the application of antigen retrieval, which enables the detection of a wide range of antigens in FFPT, the method itself is not standardized. This myriad of variables makes it inappropriate to provide meaningful comparisons of results obtained in different laboratories and even in the same laboratory, as in current practice, each specimen experiences different preanalytical variables. Furthermore, variables in interpretation exist and cutoff thresholds for positivity differ. Failure to recognize false-positive and false-negative stains leads to further errors of quantitative measurement. Many of the problems relating to the technology and interpretation of immunostaining originate from failure to recognize that this procedure is different from other histological stains and involves many more steps that cannot be monitored until the end result is attained. While several remedial measures can be suggested to address some of these problems, accurate and reproducible quantitative assessment of immunostains presently remains elusive as important variables that impact on antigen preservation in the paraffin-embedded biopsy -cannot be standardized.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21370005     DOI: 10.1007/978-1-61779-055-3_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control.

Authors:  Kodela Vani; Seshi R Sompuram; Anika K Schaedle; Anuradha Balasubramanian; Monika Pilichowska; Stephen Naber; Jeffrey D Goldsmith; Kueikwun G Chang; Farzad Noubary; Steven A Bogen
Journal:  J Histochem Cytochem       Date:  2017-06-30       Impact factor: 2.479

2.  Homocysteine-mediated modulation of mitochondrial dynamics in retinal ganglion cells.

Authors:  Preethi S Ganapathy; Richard L Perry; Amany Tawfik; Robert M Smith; Elizabeth Perry; Penny Roon; B Renee Bozard; Yonju Ha; Sylvia B Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-25       Impact factor: 4.799

Review 3.  Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice.

Authors:  Lawrence D True
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

4.  Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.

Authors:  Johann S de Bono; Adam Sharp; Adam G Sowalsky; Ines Figueiredo; Rosina T Lis; Ilsa Coleman; Bora Gurel; Denisa Bogdan; Wei Yuan; Joshua W Russo; John R Bright; Nichelle C Whitlock; Shana Y Trostel; Anson T Ku; Radhika A Patel; Lawrence D True; Jonathan Welti; Juan M Jimenez-Vacas; Daniel Nava Rodrigues; Ruth Riisnaes; Antje Neeb; Cynthia T Sprenger; Amanda Swain; Scott Wilkinson; Fatima Karzai; William L Dahut; Steven P Balk; Eva Corey; Peter S Nelson; Michael C Haffner; Stephen R Plymate
Journal:  Clin Cancer Res       Date:  2022-08-15       Impact factor: 13.801

5.  Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas.

Authors:  Caroline Kampf; Ingmarie Olsson; Urban Ryberg; Evelina Sjöstedt; Fredrik Pontén
Journal:  J Vis Exp       Date:  2012-05-31       Impact factor: 1.355

6.  Rapid two-temperature formalin fixation.

Authors:  David Chafin; Abbey Theiss; Esteban Roberts; Grace Borlee; Michael Otter; Geoffrey S Baird
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

7.  A texture based pattern recognition approach to distinguish melanoma from non-melanoma cells in histopathological tissue microarray sections.

Authors:  Elton Rexhepaj; Margrét Agnarsdóttir; Julia Bergman; Per-Henrik Edqvist; Michael Bergqvist; Mathias Uhlén; William M Gallagher; Emma Lundberg; Fredrik Ponten
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

8.  Immunohistochemical detection of a unique protein within cells of snakes having inclusion body disease, a world-wide disease seen in members of the families Boidae and Pythonidae.

Authors:  Li-Wen Chang; Ann Fu; Edward Wozniak; Marjorie Chow; Diane G Duke; Linda Green; Karen Kelley; Jorge A Hernandez; Elliott R Jacobson
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

9.  Tissue Thickness Interferes With the Estimation of the Immunohistochemical Intensity: Introduction of a Control System for Managing Tissue Thickness.

Authors:  Shinobu Masuda; Ryohei Suzuki; Yuriko Kitano; Haruna Nishimaki; Hiroko Kobayashi; Yoko Nakanishi; Hideo Yokoi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-02-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.